Viewing nowCombinationSitaplus Sustained-Release Tablet 50/500 mg (Sitagliptin, Metformin)
Sitagliptin Hydrochloride Hydrate 56.69mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
CMG Pharmaceutical Co., Ltd.

MFDS item code 202301870 · Approved 2023.06.20 · Insurance code 648604600
Improvement of glycemic control in patients with type 2 diabetes mellitus
This medication is used in combination with sitagliptin and metformin to assist in controlling blood sugar in patients with type 2 diabetes. It is prescribed when additional blood sugar management is needed alongside dietary and exercise therapy. In other words, this medication helps effectively improve blood sugar levels in diabetes patients.
In antihyperglycemic therapy, the dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. To reduce gastrointestinal adverse reactions caused by metformin, this medicine should be taken with a meal once daily, preferably in the evening, and the dose should be increased gradually. To maintain the extended-release characteristics, swallow this medicine whole without splitting, crushing, grinding, or chewing it. Take 1 tablet of this medicine 100/1000 mg extended-release tablet once daily. Patients taking this medicine 50/500 mg extended-release tablet or 50/1000 mg extended-release tablet should take 2 tablets at the same time once daily. 1. Patients not currently receiving metformin: For patients with no previous experience with antidiabetic drug therapy who do not achieve adequate glycemic control with monotherapy, or for whom adequate glycemic control cannot be achieved with sitagliptin monotherapy, the initial total daily dose of this medicine is sitagliptin 100 mg and metformin 1000 mg. If adequate glycemic control cannot be achieved with the initial dose, the dose may be increased gradually up to the maximum recommended daily dose of metformin, 2000 mg, to reduce gastrointestinal adverse reactions caused by metformin. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medicine. 2. Patients receiving metformin: For patients who do not achieve adequate glycemic control with metformin monotherapy, the recommended initial total daily dose of this medicine is sitagliptin 100 mg and the patient's current dose of metformin. Patients switching from concomitant therapy with sitagliptin and metformin to this medicine may start at their current doses of sitagliptin and metformin. Patients who were receiving immediate-release metformin at a dose of 850 mg or 1000 mg twice daily may start this medicine at a dose of 2 tablets of the 50/1000 mg extended-release tablet once daily. 3. Patients who do not achieve adequate glycemic control with concomitant therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial total daily dose of this medicine is sitagliptin 100 mg, and the initial dose of metformin should be determined based on the patient's blood glucose level and current dose. The dose should be increased gradually to reduce gastrointestinal adverse reactions caused by metformin. When administered concomitantly with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia. Patients with renal impairment This medicine may be used in patients with moderate renal impairment stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2) who do not have other symptoms that may increase the risk of lactic acidosis, with the following dose adjustment. Treatment should not be initiated with this medicine because the starting dose of metformin is 500 mg or 850 mg once daily. The maximum recommended dose of metformin is 1000 mg daily. Renal function should be monitored carefully every 3-6 months. If renal function decreases to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medicine should be discontinued immediately.
This medication contains two active ingredients: sitagliptin and metformin. Sitagliptin can cause severe allergic reactions in some patients, which may include anaphylaxis (acute allergic shock), angioedema (swelling of the skin or mucous membranes), and severe skin conditions such as Stevens-Johnson syndrome. These hypersensitivity reactions can occur within the first three months of starting the medication, so if symptoms such as skin rash or difficulty breathing occur, you should stop taking the medication immediately and consult a doctor. Additionally, this medication can cause acute pancreatitis, a serious inflammation of the pancreas, so if symptoms such as abdominal pain, nausea, or vomiting occur while taking it, you should stop taking it immediately and inform healthcare personnel. The metformin component can cause a rare but serious condition called lactic acidosis, which is a buildup of lactic acid in the blood. This condition is particularly risky for patients with impaired kidney function, dehydration, severe infections, or heart failure. Therefore, it should not be taken in these situations. Patients with moderate to severe renal impairment, acute heart failure, acute myocardial infarction, sepsis, and those undergoing radiocontrast iodine testing should not be administered this medication. Pregnant women or those who may become pregnant and nursing mothers should also avoid using this medication. When taking this medication, it is important to be cautious due to the increased risk of hypoglycemia or lactic acidosis arising from irregular eating habits, insufficient meal sizes, strenuous exercise, or interactions with other medications. This medication should also be used cautiously in individuals with allergies to certain colorants. During use, gastrointestinal disturbances, headaches, dizziness, rashes, and other side effects may occur, so it is important to consult healthcare personnel if any unusual symptoms arise.
Not everyone experiences these, and they can vary from person to person.
This medication is sensitive to air and moisture, so it should be stored in a tightly sealed container. Also, it should be kept in an environment that is neither too hot nor too cold, ideally at room temperature between 1°C and 30°C.
Light blue, oval-shaped, biconvex sustained-release film-coated tablet
Bottle - 100 tablets/bottle, Bottle - 30 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationSitagliptin Hydrochloride Hydrate 56.69mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
CMG Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 113.4mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 113.4mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Korea Hutech Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.